REFERENCES
- Ajaiyeoba A I. Malignant melanoma of the eyelid in the black—case report. West African J Med 1993; 12: 177–9, [CSA]
- Amato M, Esmaeli B, Ahmadi M A, et al. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthal Plast Reconstr Surg 2003; 19: 102–6, [INFOTRIEVE], [CSA]
- Andersson A P, Gottlieb J, Drzewiecki K T, et al. Skin melanoma of the head and neck. Prognostic factors and recurrence-free survival in 512 patients. Cancer 1992; 69: 1153–6, [INFOTRIEVE], [CSA]
- Armstrong B K. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun. J Dermatol Surg Oncol 1988; 14: 835–49, [INFOTRIEVE], [CSA]
- Balch C M, Buzaid A C, Soong S J, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19: 3635–48, [INFOTRIEVE], [CSA]
- Balch C M, Houghton A N, Sober A J, et al. Cutaneous Melanoma, 3rd ed. Quality Medical Publishing, St. Louis 1998
- Balch C M, Soong S J, Gershenwald J E, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19: 3622–34, [INFOTRIEVE], [CSA]
- Balch C M, Urist M M, Karakcusis C P, et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1–4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262–7, [INFOTRIEVE], [CSA]
- Barnhill R L, Fandrey K, Levy M A, et al. Angiogenesis and tumour progression of melanoma. Quantification of vascularity in melanocytic naevi and cutaneous malignant melanoma. Laboratory Invest 1992; 67: 331–7, [CSA]
- Berwick M, Armstrong B K, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97: 195–9, [INFOTRIEVE], [CSA]
- Bishop D T, Demenais F, Goldstein A M, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94: 894–903, [INFOTRIEVE], [CSA]
- Blessing K, McLaren K M, McLean A, Davidson P. Thin malignant melanomas (< 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990; 17: 389–95, [INFOTRIEVE], [CSA]
- Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902–8, [INFOTRIEVE], [CSA]
- Büttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995; 75: 2499–506, [CSA], [CROSSREF]
- Carucci J A. Intralesional interferon alfa for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. Arch Dermatol 2000; 136: 1415–6, [INFOTRIEVE], [CSA], [CROSSREF]
- Christenson L J. Management of lentigo maligna. Dermatol Nursing 2004; 16: 495–523, [CSA]
- Clark W H, Elder D E, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81: 1893–1904, [INFOTRIEVE], [CSA]
- Clark W H, From L, Bernardino E A, Mihm M C. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 705–26, [CSA]
- Clark W H, Mihm M C. Lentigo maligna and lentigo maligna melanoma. Am J Pathol 1969; 55: 39–54, [INFOTRIEVE], [CSA]
- Cohen L M. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33: 923–36, [INFOTRIEVE], [CSA], [CROSSREF]
- Collin J RO, Garner A, Allen L H, Hungerford J L. Malignant melanoma of the eyelid and conjunctiva. Aust N Z J Ophthalmol 1986; 14: 29–34, [INFOTRIEVE], [CSA]
- Cook B E, Bartley G B. Treatment options and future prospects for the management of eyelid malignancies. Ophthalmology 2001; 108: 2088–98, [INFOTRIEVE], [CSA], [CROSSREF]
- Cornejo P, Vanaclocha F, Polimon I, Del Rio R. intralesional interferon treatment of lentigo maligna. Arch Dermatol 2000; 136: 428–30, [INFOTRIEVE], [CSA], [CROSSREF]
- De Wit P EJ, Moretti S, Koenders P G, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumour progression. J Invest Dermatol 1992; 99: 168–173, [INFOTRIEVE], [CSA], [CROSSREF]
- Dhawan S S, Wolf D J, Rabinovitz H S, Poulos E. Lentigo maligna. Arch Dermatol 1990; 126: 928–30, [INFOTRIEVE], [CSA], [CROSSREF]
- Esmaeli B. Sentinel node biopsy as a tool for accurate staging of eyelid and conjunctival malignancies. Curr Opin Ophthalmol 2002; 13: 317–23, [INFOTRIEVE], [CSA], [CROSSREF]
- Esmaeli B, Wang B, Deavers M, et al. Prognostic factors for survival in malignant melanoma of the eyelid skin. Ophthal Plast Reconstr Surg 2000; 16: 250–7, [INFOTRIEVE], [CSA], [CROSSREF]
- Esmaeli B, Youssef A, Naderi A, et al. Margins of excision for cutaneous melanoma of the eyelid skin. Ophthal Plast Reconstr Surg 2003; 19: 96–101, [INFOTRIEVE], [CSA]
- Everall J D, Dowd P M. Diagnosis, prognosis and treatment of melanoma. The Lancet 1977; 2: 286–9, [CSA], [CROSSREF]
- Fitzpatrick T B, Johnson R A, Wolff K, et al. Color Atlas and Synopsis of Clinical Dermatology, 3rd ed. McGrawHill, New York 1997
- Fitzpatrick T B, Szabo G. The melanocyte: cytology and cytochemistry. J Invest Dermatol 1959; 32: 197–209, [INFOTRIEVE], [CSA]
- Friedman K P, Wahl R L. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004; 34: 242–53, [INFOTRIEVE], [CSA], [CROSSREF]
- Fuchs U, Kiuela T, Liesto K, et al. Prognosis of conjunctival melanomas in relation to histopathological features. Br J Cancer 1989; 59: 261–7, [INFOTRIEVE], [CSA]
- Gadd M A, Cosimi A B, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999; 134: 381–7, [INFOTRIEVE], [CSA], [CROSSREF]
- Garner A, Koornneef L, Levene A, Collin J RO. Malignant melanoma of the eyelid skin: histopathology and behaviour. Br J Opthalmol 1985; 69: 180–6, [CSA]
- Gershenwald J E, Colome M I, Thompson W, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253–60, [INFOTRIEVE], [CSA]
- Gershenwald J E, Thompson W, Mansfield P F, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage i or ii melanoma patients. J Clin Oncol 1999; 17: 976–83, [INFOTRIEVE], [CSA]
- Glat P, Longaker M T, Jelks E B, et al. Periorbital melanocytic lesions: Excision and reconstruction in 40 patients. Plast Reconstr Surg 1998; 102: 19–27, [INFOTRIEVE], [CSA]
- Gleason J F, Bhartia P K, Herman J R, et al. Record low global ozone in 1992. Science 1993; 260: 523–6, [CSA]
- Grossniklaus H E, McLean I W. Cutaneous melanoma of the eyelid. Clinicopathologic features. Ophthalmology 1991; 98: 1867–73, [INFOTRIEVE], [CSA]
- Haider S A, Thaller V T. Lid melanoma and parkinsonism. Br J Ophthalmol 1992; 76: 246–7, [INFOTRIEVE], [CSA]
- Harris M N, Shapiro R L, Roses D F. Malignant melanoma. Primary surgical management (excision and node dissection) based on pathology and staging. Cancer 1995; 75: 715–25, [INFOTRIEVE], [CSA], [CROSSREF]
- Herlyn M, Thurin J, Balaban G, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985; 45: 5670–6, [INFOTRIEVE], [CSA]
- Hill D C, Gramp A A. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australasian J Dermatol 1999; 40: 25–30, [CSA], [CROSSREF]
- Jelfs P L, Giles G, Shugg D, et al. Cutaneous malignant melanoma in Australia, 1989. Med J Austr 1994; 161: 182–7, [CSA]
- Keilholz U, Weber J, Finke J H, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunther 2002; 25: 97–138, [CSA], [CROSSREF]
- Kelly J W, Sagebiel R W, Calderon W, et al. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984; 200: 759–63, [INFOTRIEVE], [CSA]
- Kerbel R S. A cancer therapy resistant to resistance. Nature 1997; 390: 335–6, [INFOTRIEVE], [CSA], [CROSSREF]
- Kirkwood J M, Strawderman M H, Ernstoff M S, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17, [INFOTRIEVE], [CSA]
- Koh H K, Michalik E, Sober A J, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984; 2: 994–1001, [INFOTRIEVE], [CSA]
- Kretschmer L, Hilgers R, Möhrle M, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004; 40: 212–8, [INFOTRIEVE], [CSA], [CROSSREF]
- Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am 2005; 43: 23–33, [INFOTRIEVE], [CSA], [CROSSREF]
- Machet L, Nemeth-Normand F, Giraudeau B, et al. L'échographie ganglionnaire dans la surveillance des patients atteints de mélanome: étude monocentrique d'une cohorte de 373 patients. Ann Dermatol Venereol 2004; 131: 1127, [CSA]
- Malhotra R, Chen C, Huilgol S C, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology 2003; 110: 2011–8, [INFOTRIEVE], [CSA]
- Margo C E. Pigmented lesions of the eyelid. Principles and Practices of Ophthalmology, 2nd ed., D M Albert, F A Jakobiec. Saunders, Philadelphia 2000; 3430–46
- Margo C E, Duncan W C, Rich A, et al. Periocular cutaneous melanoma arising in a radiotherapy field. Ophthal Plast Reconstr Surg 2004; 20: 319–20, [INFOTRIEVE], [CSA]
- Massi D, Nardini P, De Giorgi V, Carli P. Simultaneous occurrence of multiple melanoma in situ on sun-damaged skin (lentigo maligna), solar lentigo and labile melanosis: the value of dermoscopy in diagnosis. J Eur Acad Dermatol Venereol 1999; 13: 193–7, [INFOTRIEVE], [CSA], [CROSSREF]
- McKee PH. Pathology of the Skin with Clinical Correlations, 2nd Edition. Times Mirror International Publishers Limited, London 1997
- Mcneer G, Das Gupta T. Prognosis in malignant melanoma. Surgery 1964; 56: 512–8, [CSA]
- Morton D L, Wen D R, Foshag L J, et al. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993; 11: 1751–6, [INFOTRIEVE], [CSA]
- Munoz C M, Sanchez J L, Martin-Garcia R F. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 2004; 30: 1543, [INFOTRIEVE], [CSA], [CROSSREF]
- Naylor M F, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149: 66–9, [INFOTRIEVE], [CSA], [CROSSREF]
- NIH Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. J Am Med Assoc 1992; 268: 1314–9, [CSA], [CROSSREF]
- Nijhawan N, Ross M I, Diba R, et al. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthal Plast Reconstr Surg 2004; 20: 291–5, [INFOTRIEVE], [CSA]
- Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma. Cancer 1999; 85: 2391–9, [INFOTRIEVE], [CSA], [CROSSREF]
- Pacifico M D, Grover R, Richman P I, et al. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005; 115: 367–75, [INFOTRIEVE], [CSA], [CROSSREF]
- Patel B CK, Egan C A, Lucius R W, et al. Cutaneous malignant melanoma and oculodermal melanocytosis (nevus of Ota): Report of a case and review of the literature. J Am Acad Dermatol 1998; 38: 862–5, [INFOTRIEVE], [CSA], [CROSSREF]
- Polito E, Leccisotti A. Primary and secondary orbital melanomas: a clinical and prognostic study. Ophthal Plast Reconstr Surg 1995; 11: 169–81, [INFOTRIEVE], [CSA]
- Punt C JA. The use of interferon-alfa in the treatment of cutaneous melanoma: a review. Melanoma Res 1998; 8: 95–104, [INFOTRIEVE], [CSA]
- Reintgen D S, Cox E B, McCarty K S, Jr, et al. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198: 379–85, [INFOTRIEVE], [CSA]
- Robinson J K. Margin control for lentigo maligna. J Am Acad Dermatol 1994; 31: 79–85, [INFOTRIEVE], [CSA]
- Robinson J K. Use of digital epiluminescence microscopy to help define the edge of lentigo maligna. Arch Dermatol 2004; 140: 1095–100, [INFOTRIEVE], [CSA], [CROSSREF]
- Rodriguez-Sains R S. Melanoma of the eyelid. Plast Reconstr Surg 1999; 103: 2080–1, [INFOTRIEVE], [CSA]
- Shields J A, Shields C L. Atlas of Eyelid & Conjunctival Tumors. Lippincott Williams & Wilkins, Philadelphia 1999
- Shiose S, Sakamoto T, Yoshikawa H, et al. Gene transfer of a soluble receptor of vegf inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Science 2000; 41: 2395–403, [CSA]
- Sim F H, Taylor W F, Ivins J C, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 1978; 41: 948–56, [INFOTRIEVE], [CSA], [CROSSREF]
- Sober A J, Chuang T Y, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45: 579–86, [INFOTRIEVE], [CSA], [CROSSREF]
- Stang A, Stabenow R, Eisenger B, Jöckel K H. Site- and gender-specific time trend analyses of the incidence of skin melanomas in the former German Democratic Republic (GDR) including 19351 cases. Eur J Cancer 2003; 39: 1610–8, [INFOTRIEVE], [CSA], [CROSSREF]
- Stannard C E, Sealy G RH, Hering E R. malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology 2000; 107: 951–8, [INFOTRIEVE], [CSA], [CROSSREF]
- Tahery D P, Goldberg R, Moy R L. Malignant melanoma of the eyelid. J Am Acad Dermatol 1992; 27: 17–21, [INFOTRIEVE], [CSA]
- Traboulsi E I, Zimmerman L E, Manz J H. Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arch Ophthalmol 1988; 106: 1059–61, [INFOTRIEVE], [CSA]
- Tsao H, Atkins M B, Sober A J. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998–1012, [INFOTRIEVE], [CSA], [CROSSREF]
- Tsao H, Sober A. Acquired precursor lesions and markers of increased risk for cutaneous melanoma. Cutaneous Melanoma, 4th ed., C Balch, A Houghton, A Sober, S Soong. Quality Medical Publishing, St. Louis 2003; 121–34
- Urist M M, Balch C M, Soong S J, et al. Head and neck melanoma in 534 clinical stage i patients. Ann Surg 1984; 200: 769–75, [INFOTRIEVE], [CSA]
- Vaziri M, Buffam F V, Matrinka M, et al. Clinicopathologic features and behavior of cutaneous eyelid melanoma. Ophthalmology 2002; 109: 901–8, [INFOTRIEVE], [CSA], [CROSSREF]
- Veronesi U, Adamus J, Bandiera D C, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297: 627–30, [INFOTRIEVE], [CSA]
- Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159–62, [INFOTRIEVE], [CSA]
- Wayte D M, Helwig E B. Melanotic freckle of hutchinson. Cancer 1968; 21: 893–911, [INFOTRIEVE], [CSA], [CROSSREF]
- Weinstock M A, Sober A J. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116: 303–10, [INFOTRIEVE], [CSA], [CROSSREF]
- World Health Organization. Solar and Ultraviolet Radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, Lyon 1992; vol. 55
- Yu L L, Flotte T J, Tanabe K K, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999; 86: 617–27, [INFOTRIEVE], [CSA], [CROSSREF]